by Caleb Michael Parker
Weekly pharmacy news recaps. This podcast covers all important news in the world of pharmacy for the layman and pharmacist alike. Free from opinion and bias, we provide you with the most up-to-date and accurate information available from a variety of news sources. Episodes are posted weekly on Wednesdays or Thursdays DISCLAIMER: All opinions are my own and are not the views of my employer(s).
Language
🇺🇲
Publishing Since
3/1/2021
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
July 15, 2021
<p>Thank you for listening to this week's episode! Be sure to subscribe for weekly updates in the world of pharma.</p> <p><br></p> <p>LINKS:</p> <ul> <li><strong>Story #1 </strong><a href="https://www.biopharmadive.com/news/fda-investigation-aduhelm-alzheimers-drug-approval-biogen/603122/"><u><strong>https://www.biopharmadive.com/news/fda-investigation-aduhelm-alzheimers-drug-approval-biogen/603122/<br> </strong></u></a></li> <li><strong>Link to Janet Woodcock’s tweet: </strong><a href="https://twitter.com/DrWoodcockFDA/status/1413540801934774283"><u><strong>https://twitter.com/DrWoodcockFDA/status/1413540801934774283<br> </strong></u></a></li> <li><strong>Story #2 </strong><a href="https://www.biopharmadive.com/news/lilly-acquire-protomer-glucose-sensitive-insulin/603325/"><u><strong>https://www.biopharmadive.com/news/lilly-acquire-protomer-glucose-sensitive-insulin/603325/<br> </strong></u></a></li> <li><strong>Story #3 </strong><a href="https://www.statnews.com/2021/07/13/aduhelm-left-room-lilly-ceo-eyes-competition-with-biogen-alzheimers-drug/"><u><strong>https://www.statnews.com/2021/07/13/aduhelm-left-room-lilly-ceo-eyes-competition-with-biogen-alzheimers-drug/<br> </strong></u></a></li> <li><strong>Link to Lilly’s investor site https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy</strong></li> </ul> <p><strong>TAGS:</strong></p> <p><strong>#pharmacist #medicine #health #medical #pharmacology #pharma #healthcare #covid #pharmacystudent #farmacia #doctor #pharmacists #gpat #pharmacylife #pharmacytechnician #pharmacyschool #doctors #pharmd #niper #pharmaceuticals #hospital #nurse #coronavirus #science #pharmacistlife #mbbs #drugs #skincare #industry #pharmacy<br> </strong></p>
July 8, 2021
<p>Thank you for tuning in to Take Once a Week, if you like this episode, be sure to subscribe!</p> <p><br></p> <p>LINKS to stories:</p> <ul> <li><a href="https://www.biopharmadive.com/news/scorpion-axel-hoos-ceo-gsk-biotech-startup/602966/"><u><strong>https://www.biopharmadive.com/news/scorpion-axel-hoos-ceo-gsk-biotech-startup/602966/<br> </strong></u></a></li> <li><a href="https://endpts.com/spurring-a-biotech-craze-of-its-own-the-uk-plots-out-public-private-investment-plan-as-part-of-1b-industry-infusion/"><u><strong>https://endpts.com/spurring-a-biotech-craze-of-its-own-the-uk-plots-out-public-private-investment-plan-as-part-of-1b-industry-infusion/<br> </strong></u></a></li> <li><a href="https://www.fiercepharma.com/pharma/pfizer-victory-vyndaqel-copay-lawsuit-could-spur-drug-pricing-gold-rush-former-hhs-member"><u><strong>https://www.fiercepharma.com/pharma/pfizer-victory-vyndaqel-copay-lawsuit-could-spur-drug-pricing-gold-rush-former-hhs-member<br> </strong></u></a></li> <li><a href="https://www.pharmatimes.com/news/jardiance_becomes_first_sglt2_inhibitor_to_show_benefit_in_hfpef_1372804"><u><strong>https://www.pharmatimes.com/news/jardiance_becomes_first_sglt2_inhibitor_to_show_benefit_in_hfpef_1372804<br> </strong></u></a></li> </ul> <p><u><strong>Tags:</strong></u></p> <p>pharmacy #pharmacist #medicine #health #medical #pharmacology #pharma #healthcare #covid #pharmacystudent #farmacia #doctor #pharmacists #gpat #pharmacylife #pharmacytechnician #pharmacyschool #doctors #pharmd #niper #pharmaceuticals #hospital #nurse #coronavirus #science #pharmacistlife #mbbs #drugs #skincare #industry</p>
June 9, 2021
<p>In this episode of Take Once a Week, we will discuss the approval of Biogen's Aduhelm as well as some of the major discussions that occurred this past week at ASCO. If you like this episode and others like it, be sure to subscribe!</p> <p><br></p> <p>LINKS TO ALL STORIES:</p> <ul> <li><a href="https://www.biopharmadive.com/news/biogen-aduhelm-confirmatory-study-fda-approval/601422/"><u><strong>https://www.biopharmadive.com/news/biogen-aduhelm-confirmatory-study-fda-approval/601422/<br> </strong></u></a></li> <li><a href="https://www.biopharmadive.com/news/a-first-of-its-kind-alzheimers-drug-raises-heavy-questions-around-who-will/601434/"><u><strong>https://www.biopharmadive.com/news/a-first-of-its-kind-alzheimers-drug-raises-heavy-questions-around-who-will/601434/<br> </strong></u></a></li> <li><a href="https://www.biopharmadive.com/news/asco-2021-takeaways-adjuvant-immunotherapy-fate-cullinan/601384/"><u><strong>https://www.biopharmadive.com/news/asco-2021-takeaways-adjuvant-immunotherapy-fate-cullinan/601384/<br> </strong></u></a></li> <li><strong>https://www.fiercepharma.com/pharma/1-2b-deal-for-molnupiravir-u-s-bets-merck-to-finally-provide-effective-covid-19-treatment<br> </strong></li> </ul> <p><strong>#pharmacy #news #pharma #pharmaupdates #podcast #academic #vaccine #alzheimers #developments</strong></p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
Weekly pharmacy news recaps. This podcast covers all important news in the world of pharmacy for the layman and pharmacist alike.
Free from opinion and bias, we provide you with the most up-to-date and accurate information available from a variety of news sources.
Episodes are posted weekly on Wednesdays or Thursdays
DISCLAIMER: All opinions are my own and are not the views of my employer(s).
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
No, this podcast does not typically feature guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.